Latest news with #Volpara
Yahoo
7 days ago
- Business
- Yahoo
BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement
Volpara software is used to assess the breast density of more than 1 million Australian womenannually WELLINGTON, New Zealand, June 2, 2025 /PRNewswire/ -- Volpara Health, a Lunit a company and global leader in software for the early detection of breast cancer, today applauded the significant advancement in breast health management with BreastScreen Australia's new position on breast density reporting. This new guidance recommends that all BreastScreen services in Australia provide breast density information to clients, enhancing awareness and understanding of this critical risk factor. A Step Toward More Accurate and Personalised Breast Cancer Screening Volpara's Scorecard software is utilised to measure the breast density of over 1 million women annually across Australia, including in BreastScreen Victoria and BreastScreen South Australia. This comprehensive, AI-driven approach supports physicians in making consistent, objective assessments, helping to ensure that breast cancer risk is more accurately evaluated for each patient. Volpara's volumetric breast density assessment software, including its proprietary Volpara® TruDensity™ AI algorithm, provides consistent and precise breast density measurements. Cleared by the Therapeutic Goods Administration (TGA), FDA, Health Canada, and CE-marked in Europe, this technology has been validated in more than 400 scientific articles and research abstracts, underscoring its reliability and accuracy. "We've been collaborating with leading clinicians and researchers worldwide for over a decade to make critical information about breast composition and its link to breast cancer more accessible," said Craig Hadfield, CEO, Volpara Health. "The new guidelines from BreastScreen Australia validate our focus on applying tech and AI advancements to breast density and are a significant step forward in enhancing the experience and understanding for women and their healthcare providers. We encourage women to contact their local healthcare provider and ask how they assess breast density." Understanding Breast Density: A Critical Risk Factor Breast density is an important factor in both breast cancer detection and risk assessment. It has been linked to an increased risk of developing breast cancer, while also making it more challenging to detect cancer through mammography. In Australia, approximately 40% of women have dense breasts, including 12% with extremely dense breasts. As breast density increases, the accuracy of mammography decreases. Research published in Radiology reveals that mammography can miss up to 50% of cancers in women with the densest breast tissue. Since both dense breast tissue and tumours appear white on a mammogram, cancers are often concealed, potentially delaying diagnosis. Studies confirm that early detection rates improve significantly when women with very dense breasts receive additional imaging, such as ultrasound or MRI, as part of their regular screening regimen. The Path Forward: Embracing Personalised Screening Breast density information is also integrated into several risk models, which helps identify women at higher risk of breast cancer who may benefit from supplemental screening. Volpara Scorecard is the only commercial automated software validated for use in both the Tyrer-Cuzick 8 and CanRisk (BOADICEA) riskmodels, providing consistent and robust breast density measurements. With this new guidance, Volpara is poised to play an essential role in supporting risk assessment and personalised screening in Australia, further advancing the goal of improving outcomes for women. The importance of personalised screening has also been recognised by other Australian health bodies, with Medicare recently introducing reimbursement for high-risk breast MRI screening based on Tyrer-Cuzick 8 or CanRisk risk assessment. This marks a growing recognition of the need for tailored breast cancer screening strategies that consider individual risk factors, including breast density. About Volpara Health Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit Logo - View original content: SOURCE Volpara Health Error in retrieving data Sign in to access your portfolio Error in retrieving data
Korea Herald
19-05-2025
- Business
- Korea Herald
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI for cancer diagnostics and therapeutics, today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies. Since acquiring Volpara, Lunit has significantly expanded its presence across North America. By June 2025, Lunit's AI solutions for digital breast tomosynthesis (Lunit INSIGHT DBT) and mammography analysis (Lunit INSIGHT MMG) will be deployed at over 200 imaging centers and hospitals across the U.S., with approximately 350 to 400 radiologists utilizing its technology. Together, Lunit and Volpara now power more than one million annual mammograms across North America — a major step forward in the company's U.S. growth strategy. Lunit's growing customer base includes leading healthcare providers such as Rezolut, SimonMed Imaging, and UC Davis Health, reflecting its strengthening position in the U.S. medical imaging market. In addition to its expanding U.S. footprint, Lunit and Volpara introduced the concept of a comprehensive Ecosystem for Cancer Detection and Care at RSNA 2024. The Ecosystem is designed to unify AI technologies for lesion detection, workflow optimization, quality control, and patient engagement—empowering clinicians with actionable insights and scalable solutions across the cancer care continuum. Lunit and Volpara also demonstrated the complementary value of combining Lunit INSIGHT Risk and Volpara Risk Pathways at RSNA 2024—offering a glimpse into how imaging-based and clinical data may be used together to personalize breast cancer risk assessment. The two solutions were shown as a prototype to work in tandem, that would predict the likelihood of breast cancer development within 1 to 5 years, to enable earlier interventions, more personalized care, and redefine standards for breast cancer screening and management. "The successful integration of Lunit and Volpara has accelerated our mission to transform cancer diagnostics globally, and the momentum we've built in the United States marks just the beginning," said Brandon Suh, CEO of Lunit. "By combining Lunit's AI innovation with Volpara's breast health expertise, we're delivering a new standard of comprehensive support for clinicians—enhancing early detection, improving screening quality, optimizing workflows, and ultimately helping providers deliver better outcomes for patients worldwide. With our expanded footprint and comprehensive ecosystem, we are poised to lead the future of cancer care." Lunit plans to further expand its U.S. operations, building on its strong foundation with next-generation AI solutions, dedicated clinical support, and a growing ecosystem designed to shape the future of cancer detection and care. Founded in 2013, Lunit (KRX: is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology —and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at
Yahoo
23-03-2025
- Health
- Yahoo
Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence
CANBERRA, Australia, March 24, 2025 /PRNewswire/ -- Volpara Health, a global leader in AI-powered breast health solutions and a subsidiary of Lunit, today announced two major milestones: Volpara density is now a validated input to the BOADICEA breast cancer risk model. A record of 21 independent abstracts featuring Lunit and Volpara solutions were presented at ECR 2025. Volpara density now integrated into BOADICEA breast cancer risk model Volpara volumetric breast density assessment is now a validated input to the newly released version of the BOADICEA breast cancer risk model. This marks a significant milestone, as Volpara density is now integrated into two different breast cancer risk models—Tyrer-Cuzick and BOADICEA, sometimes referred to as IBIS or CanRisk, respectively. Any Volpara customers can use their Volpara density information via CanRisk today. CanRisk is endorsed by international societies and guidelines for use in Australia, the EU, the UK, the US, and Canada. Studies have shown the use of Volpara density in BOADICEA to improve model accuracy compared to using BI-RADS density categories, enhancing breast cancer risk assessment capabilities for healthcare providers worldwide. A record-high 21 Lunit and Volpara research abstracts at ECR 2025 At the European Congress of Radiology (ECR) 2025, Lunit and Volpara's solutions were featured in a record-high 21 independent research abstracts. This milestone highlights the growing impact of AI-driven breast health solutions in the global radiology community, reinforcing Volpara's and Lunit's commitment to advancing cancer detection and patient care through innovation and scientific research. About Volpara Health Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit Volpara Media Contact: Andrew Thompson-YoungClarity Quest Andrew@ Logo - View original content: SOURCE Volpara Health
Yahoo
03-03-2025
- Business
- Yahoo
Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the appointment of Craig Hadfield as the new CEO of its subsidiary, Volpara Health Technologies. Craig, who currently serves as Volpara's Chief Customer and Financial Officer, will assume the role effective April 1, 2025. Craig brings nearly nine years of leadership experience to Volpara, where he has played a pivotal role in scaling the company from a startup to an industry leader in breast health solutions. Since joining Volpara in 2016, he has overseen financial operations, strategic acquisitions, and the company's transition to a SaaS-based model. Under his leadership as CFO from 2017 to 2024, Volpara's annual recurring revenue grew up to over US$34 million, and the company achieved cash flow break-even for the first time in 2023. Craig was also instrumental in Volpara's acquisition by Lunit in 2023 and has since led its customer success and implementation teams. "We are confident that Craig's leadership will drive Volpara's continued success and innovation in breast health," said Brandon Suh, CEO of Lunit. "His deep understanding of Volpara's business and his proven leadership make him the ideal person to guide the company into its next phase of growth. We look forward to his continued success in driving Volpara's mission to advance breast health solutions worldwide." "I am honored to step into this role and continue leading Volpara's mission to transform breast health through innovative AI-powered solutions," said Craig. "Having been part of Volpara's journey for nearly a decade, I look forward to working with our talented team, partners, and customers to expand our impact and drive even greater value in breast cancer detection and patient care." Craig, who has worked across South Africa, New Zealand, the Bahamas, and the United States, is a qualified Chartered Accountant and previously held roles at Ernst & Young (EY) and Deloitte before joining Volpara. He holds a Bachelor of Commerce in Accounting and Finance and an Accounting Higher Diploma from the University of Witwatersrand in Johannesburg, South Africa. About Lunit Founded in 2013, Lunit (KRX: is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at About Volpara Health Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit View original content to download multimedia: SOURCE Lunit Sign in to access your portfolio
